ONCAlert | 2018 ASCO Annual Meeting

Targeting RET Alterations With Selective Inhibitor BLU-667

Vivek Subbiah, MD
Published Online: 10:45 PM, Sun April 15, 2018

Vivek Subbiah, MD, associate medical director, Clinical Center for Targeted Therapy, assistant professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses targeting RET alterations in solid tumors during the 2018 AACR Annual Meeting.

The next-generation tyrosine kinase inhibitor BLU-667 is a highly potent and selective oral inhibitor that targets oncogenic RET fusions, point mutations, and resistance mutations. RET is a rare driver of multiple, diverse tumor types including more than 60% of medullary thyroid cancers (MTC), about 10% of papillary thyroid tumors, and approximately 1% to 2% of non–small cell lung cancer (NSCLC). There are currently no approved potent therapies to target RET.

In findings from the open-label, first-in-human, phase I ARROW trial, BLU-667 appeared to be well tolerated and showed clinical benefit in patients with advanced, RET-altered solid tumors who had progressed on prior therapies. Fifty-one patients with unresectable, advanced solid tumors were enrolled on the trial, which included 29 with RET-mutant MTC, 19 with NSCLC with RET fusions, 2 with papillary thyroid cancer, and 1 with paraganglioma.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.